The recruitment process for this call is now closed

Champalimaud Foundation is actively looking for a Research Funding Manager. If you are passionate about science and ready to be challenged daily while you help bring some of the most promising research ideas in neuroscience, behaviour, physiology and cancer into reality, this opportunity may be for you.

The meeting brought together over 200 specialists from 25 countries, representing a truly international effort to advance research and clinical practice in the field of kidney diseases associated with monoclonal gammopathies.

The scientific programme featured a rich series of sessions addressing key areas in the field, including new pathophysiological insights into monoclonal gammopathies and kidney disease, innovations in diagnostic tools and biomarkers, emerging therapeutic strategies, and the latest updates from ongoing clinical trials.

These three institutions stand out for their complementary and comprehensive work, which over decades has promoted eye health and reduced the burden of visual impairment, especially in the most disadvantaged regions of the world. 

Effective Neural Dynamical System

Memming Park (Neural Dynamics Lab)

Moderation

Klaas van Gisbergen (Tissue Immunity Lab)

Venue

Champalimaud Foundation Auditorium 

Registration

Please register via this link.
 

With deep sorrow at the passing of Dr. Henrique Nabais, we pay tribute to our colleague and our friend. His unwavering dedication, leadership and professionalism earned him the highest regard and respect from all who knew him. We extend our heartfelt condolences to his family and friends.

Dr. Henrique Nabais led the Gynaecology Unit of the Champalimaud Clinical Centre since 2013. In these years, he left a profound and lasting mark on his colleagues, on the many patients he cared for, and on their families, whose trust he honoured with compassion and excellence.

An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging (MRI) scans – that is, without resorting to a biopsy. Their findings were published today, 15th of August, in the journal Radiology: Imaging Cancer.

“This is a historic step,” says Prof. Dr. Robert Schoevers, head of psychiatry at the University Medical Center Groningen (UMCG) and principal investigator of PsyPal. “After many months of preparation, we are thrilled to begin working directly with patients.”